Altimmune (NASDAQ:ALT) Given New $13.00 Price Target at B. Riley Financial

Altimmune (NASDAQ:ALT) had its price objective cut by B. Riley Financial from $18.00 to $13.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts also recently commented on the company. Citizens Jmp lowered their price objective on Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research note on Friday, November 7th. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. William Blair reissued a “market perform” rating on shares of Altimmune in a report on Thursday. Barclays assumed coverage on shares of Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $16.60.

Altimmune Stock Performance

NASDAQ ALT traded up $0.03 during trading hours on Friday, reaching $3.54. The company’s stock had a trading volume of 5,378,969 shares, compared to its average volume of 2,909,658. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. The business has a 50-day simple moving average of $4.48 and a 200 day simple moving average of $4.28. Altimmune has a 52 week low of $2.90 and a 52 week high of $7.73. The stock has a market cap of $399.42 million, a PE ratio of -3.50 and a beta of 0.13.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 54.03%. Equities research analysts predict that Altimmune will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Altimmune

In other Altimmune news, Director John Gill purchased 12,500 shares of the stock in a transaction dated Tuesday, December 23rd. The shares were bought at an average cost of $4.10 per share, with a total value of $51,250.00. Following the completion of the acquisition, the director owned 12,500 shares of the company’s stock, valued at approximately $51,250. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jerome Benedict Durso acquired 12,500 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average price of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the purchase, the director owned 12,500 shares of the company’s stock, valued at approximately $51,625. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 30,527 shares of company stock valued at $125,278. Company insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Altimmune

Several large investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock worth $247,000 after buying an additional 2,241 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Altimmune during the first quarter valued at approximately $50,000. Envestnet Asset Management Inc. increased its stake in shares of Altimmune by 48.0% during the second quarter. Envestnet Asset Management Inc. now owns 32,908 shares of the company’s stock valued at $127,000 after acquiring an additional 10,671 shares during the period. Los Angeles Capital Management LLC bought a new stake in Altimmune during the second quarter worth approximately $54,000. Finally, Geode Capital Management LLC raised its holdings in Altimmune by 13.4% during the second quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock worth $7,489,000 after purchasing an additional 228,995 shares in the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune News Summary

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Company advanced pemvidutide development — management reiterated plans to initiate a Phase 3 MASH trial in 2026, pemvidutide received FDA Breakthrough Therapy designation for MASH, and RECLAIM Phase 2 topline data in AUD is expected in 3Q 2026. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Balance sheet strengthened — company reported about $274M in cash, cash equivalents and short-term investments at year-end and completed a $75M registered direct offering in January, supporting clinical programs and runway. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Company outlined a large, 1,800‑patient Phase III MASH design and signaled cash runway into 2028 as pemvidutide advances — this reduces near-term execution risk for the lead program. Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028
• Neutral Sentiment: B. Riley cut its price target from $18 to $13 but kept a Buy rating — the new target still implies meaningful upside vs. current levels, though it reduces analyst enthusiasm relative to prior coverage. Benzinga
• Neutral Sentiment: Earnings call and transcripts are available for review — useful for investors who want management’s commentary on timelines, trial designs and cash runway. Altimmune Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Neutral Sentiment: Reported short-interest notes appear to show anomalous/zero values in public data feeds and are not a reliable signal at this time.
• Negative Sentiment: Q4 earnings missed estimates — EPS of ($0.27) vs. consensus ($0.25) and immaterial GAAP revenue ($0.03M); very large negative margins and negative ROE highlight ongoing R&D spending and lack of commercial revenue. Altimmune stock edges down on fourth quarter earnings miss

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.